Curis Inc. filings document the regulatory record of a biotechnology company focused on emavusertib (CA-4948) and related oncology-development activities. Form 8-K disclosures cover financial results, clinical and regulatory updates, material agreements, capital-structure matters and Nasdaq listing-compliance notices.
Proxy and other filings describe shareholder voting matters, authorized-share proposals, securities issuances tied to preferred stock and warrant instruments, equity incentive plans, executive compensation and governance procedures. The filing record also includes pro forma financial information related to the completed sale of the company’s interest in Curis Royalty, LLC.
Curis, Inc. is calling a virtual special stockholder meeting on March 17, 2026 to approve several actions tied to a recent financing and future equity grants. The board asks investors to increase authorized capital stock from 73,343,750 to 288,757,150 shares, including common stock from 68,343,750 to 283,757,150 shares, to support existing and potential issuances.
Stockholders are also asked to approve, under Nasdaq rules, issuing up to 26,926,675 common shares upon conversion of January 2026 Series B preferred stock and up to 80,780,025 shares on exercise of Series A, B and C warrants from a $20.2 million PIPE financing, which could add about $60.6 million in gross proceeds if all warrants are exercised for cash. A new 2026 Incentive Plan would authorize 6,407,374 fresh shares plus recycling of certain expiring awards and an annual “evergreen” increase, replacing the 2010 plan. The board stresses that failure of Proposals 1 and 2 would leave the preferred non‑convertible, the warrants non‑exercisable, restrict further equity issuance under the purchase agreement, and require repeated stockholder meetings, while approval enables needed capital access but materially increases potential dilution.
Curis, Inc. reports that it has regained compliance with Nasdaq Listing Rule 5550(b)(2), meaning its common stock currently meets Nasdaq’s minimum market value of listed securities requirement and the terms set by a Nasdaq Hearings Panel.
Under Nasdaq Listing Rule 5815(d)(4)(A), Curis will remain under a one-year discretionary Panel monitoring period. If it falls out of compliance with any Nasdaq listing rule during this time, it will not receive a cure period or extra time to fix the issue. Instead, Nasdaq staff would issue a delisting determination, after which Curis could request a new hearing, and its securities may ultimately be delisted from Nasdaq.
M28 Capital Management LP and Marc Elia report beneficial ownership of 620,167 shares of Curis Inc. common stock, equal to 4.8% of the class based on 12,928,853 shares outstanding as of November 4, 2025. This amount includes 99,108 shares issuable upon exercise of warrants held through M28 Capital Master Fund LP.
The reporting persons state they share voting and dispositive power over all 620,167 shares and have no sole voting or dispositive power. They certify the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Curis. This Amendment No. 2 is being filed to voluntarily exit the Schedule 13G reporting system after their ownership fell to 5 percent or less of the outstanding shares.
Curis, Inc. entered into a private PIPE financing, agreeing to sell 20,195 shares of Series B convertible preferred stock bundled with Series A, B and C warrants, each series initially covering 26,926,675 common shares at an exercise price of $0.75 per share. The transaction is expected to provide initial gross proceeds of approximately $20.2 million and could reach about $80.8 million if all warrants are exercised, before fees. Conversion of the preferred and exercisability of the warrants depend on stockholder approval to increase authorized common shares and approve the issuances, and are subject to beneficial ownership caps. Curis estimates that existing cash plus PIPE proceeds, excluding any warrant exercises, will extend its cash runway into 2027 as it focuses development on emavusertib in chronic lymphocytic leukemia and primary central nervous system lymphoma. The company believes the PIPE will help maintain Nasdaq listing compliance through higher stockholders’ equity, but continued listing is not assured.
Curis, Inc. filed an 8‑K/A to add unaudited pro forma financial information related to its completed sale of its interest in Curis Royalty, LLC to TPC Investments Royalty LLC, managed by Oberland Capital.
The filing includes an unaudited pro forma condensed consolidated balance sheet as of September 30, 2025, pro forma statements of operations for the nine months ended September 30, 2025, and for the year ended December 31, 2024, furnished as Exhibit 99.1.
Curis, Inc. (CRIS) filed a Form S-8 to register 1,255,000 shares of common stock for issuance under its Fifth Amended and Restated 2010 Stock Incentive Plan, as amended, and 84,750 shares issuable pursuant to inducement stock option awards granted during May 1, 2025 through October 1, 2025.
The filing incorporates by reference the company’s most recent Annual Report, Quarterly Reports, and specified Current Reports. This registration supports equity compensation and hiring tools by making additional shares available under the plan and the disclosed inducement awards.
Curis, Inc. filed its Q3 2025 10-Q reporting continued operating losses and tight liquidity. Net revenues were $3.176 million for the quarter, with a net loss of $7.729 million and net loss per share of $0.49. For the nine months, net revenues were $8.305 million and net loss totaled $26.938 million.
Cash and cash equivalents were $9.051 million as of September 30, 2025, and management disclosed conditions that raise substantial doubt about the company’s ability to continue as a going concern. Operating cash use was $20.830 million for the nine months.
Curis completed financings in March 2025 and July 2025, issuing common stock, pre‑funded warrants, and common warrants, with combined net proceeds of approximately $14.9 million. Total liabilities were $42.332 million, including $28.631 million related to the sale of future Erivedge royalties.
Subsequent event: on November 6, 2025, Curis sold its interest in Curis Royalty LLC to an Oberland affiliate for $2.5 million and obtained a release of the royalty‑related liability; Curis will no longer receive Erivedge collaboration revenues and expects to record a gain in Q4 2025.
Curis, Inc. (CRIS) completed the sale of its Erivedge business—including its interest in Curis Royalty LLC, Erivedge intellectual property, and its rights under the Genentech license—in exchange for $2.5 million upfront and a release of the company’s liability related to the prior sale of future royalties to Oberland.
The company transferred all related technology and assigned its rights and obligations under the license to Curis Royalty. Curis expects to recognize a gain in Q4 2025 and the liability tied to sold future royalties will be extinguished. Following the sale, Curis will no longer receive revenue under the Erivedge license.
Separately, Nasdaq granted an exception until November 14, 2025 to regain compliance with the market value of listed securities rule. Curis believes, as of this report, that its stockholders’ equity is well above the $2.5 million alternative threshold under Listing Rule 5550(b)(1), though the Panel’s decision is not assured.
Curis, Inc. reported that Nasdaq’s Hearings Panel granted an exception until November 14, 2025 to regain compliance with the Nasdaq Listing Rule 5550(b)(2) market value of listed securities requirement of $35,000,000.
During this period, the company must promptly notify Nasdaq of any significant events affecting compliance, and the Panel may reconsider the exception if circumstances change. The notice states there is no assurance the company will regain compliance or remain listed on Nasdaq.
Curis, Inc. received a delisting notice from Nasdaq after failing to meet the minimum market value of listed securities ($35,000,000) for 30 consecutive trading days. Nasdaq gave a 180‑day compliance period that expired on August 20, 2025, and on August 21, 2025 the Listing Qualifications Staff notified the company that its securities would be delisted unless the company requests a hearing by August 28, 2025. The company intends to request a hearing before the Nasdaq Hearings Panel, which will stay any suspension or delisting while the appeal is pending. The common stock remains listed and tradable on Nasdaq during the appeal, but there is no assurance the company will regain compliance.